
RealRate

PHARMACEUTICAL 2022

INTERCEPT PHARMACEUTICALS INC.



Rank 236 of 475



RealRate

PHARMACEUTICAL 2022

INTERCEPT PHARMACEUTICALS INC.



Rank 236 of 475

The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 231% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is -93%, being 184% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	502,292
Cost of Goods Sold	3,100
Intangible Assets	0
Liabilities, Current	166,817
Liabilities, Non-Current	544,168
Other Assets	21,354
Other Compr. Net Income	-396
Other Expenses	-86
Other Liabilities	0
Other Net Income	-35,753
Property and Equipment	3,377
Research and Development	185,272
Revenues	363,468
Selling, General and Administrative Expense	230,855

Output Variable	Value in 1000 USD
Assets	527,023
Liabilities	710,985
Expenses	419,141
Stockholders Equity	-183,962
Net Income	-91,426
Comprehensive Net Income	-91,624
Economic Capital Ratio	-93%